NASDAQ:CARACara Therapeutics Stock Price, Forecast & News

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CARA shares have increased by 22.6% and is now trading at $16.46. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cara Therapeutics.

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Cara Therapeutics.

Cara Therapeutics Inc (NASDAQ:CARA) posted its earnings results on Monday, May, 11th. The biopharmaceutical company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.01. The biopharmaceutical company earned $8.09 million during the quarter, compared to analysts' expectations of $4.83 million. Cara Therapeutics had a negative return on equity of 68.83% and a negative net margin of 480.29%. View Cara Therapeutics' earnings history.

6 Wall Street analysts have issued 1-year price targets for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate Cara Therapeutics' stock price to reach $34.83 in the next year. This suggests a possible upside of 111.6% from the stock's current price. View analysts' price targets for Cara Therapeutics.

Media coverage about CARA stock has trended extremely negative on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cara Therapeutics earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View the latest news aboutCara Therapeutics.

Cara Therapeutics saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 3,280,000 shares, a decline of 6.0% from the April 30th total of 3,490,000 shares. Based on an average daily trading volume, of 514,400 shares, the days-to-cover ratio is presently 6.4 days. Currently, 7.7% of the shares of the company are sold short. View Cara Therapeutics' Current Options Chain.

Some companies that are related to Cara Therapeutics include Axsome Therapeutics (AXSM), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Uniqure (QURE), Amarin (AMRN), Alkermes (ALKS), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Insmed (INSM), Ra Pharmaceuticals (RARX), Karuna Therapeutics (KRTX), Principia Biopharma (PRNB) and Prestige Consumer Healthcare (PBH). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cara Therapeutics investors own include Lions Gate Entertainment (LGF.A), Canopy Growth (CGC), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Insys Therapeutics (INSY), 22nd Century Group (XXII), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Novavax (NVAX) and BioMarin Pharmaceutical (BMRN).

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (7.49%), Carmignac Gestion (3.82%), Chescapmanager LLC (2.79%), State Street Corp (2.19%), ETF Managers Group LLC (1.88%) and Disciplined Growth Investors Inc. MN (1.62%). Company insiders that own Cara Therapeutics stock include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joseph William Stauffer, Mani Mohindru and Scott Terrillion. View institutional ownership trends for Cara Therapeutics.

CARA stock was sold by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, BlackRock Inc., Pinnacle Associates Ltd., UBS Group AG, Two Sigma Investments LP, Squarepoint Ops LLC, Burrage Capital Management LLC, and JPMorgan Chase & Co.. Company insiders that have sold Cara Therapeutics company stock in the last year include Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Mani Mohindru, and Scott Terrillion. View insider buying and selling activity for Cara Therapeutics.

CARA stock was purchased by a variety of institutional investors in the last quarter, including Carmignac Gestion, Orbimed Advisors LLC, ETF Managers Group LLC, Geode Capital Management LLC, DAFNA Capital Management LLC, State Street Corp, Balyasny Asset Management LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Cara Therapeutics.

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CARA stock can currently be purchased for approximately $16.46.

Cara Therapeutics has a market capitalization of $770.33 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Cara Therapeutics employs 55 workers across the globe.

The official website for Cara Therapeutics is www.caratherapeutics.com.

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700.